Pacira BioSciences, Inc. (PCRX)vsViatris Inc (VTRS)
PCRX
Pacira BioSciences, Inc.
$23.49
+1.25%
HEALTHCARE · Cap: $951.20M
VTRS
Viatris Inc
$13.50
+1.05%
HEALTHCARE · Cap: $15.39B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 1869% more annual revenue ($14.30B vs $726.41M). PCRX leads profitability with a 1.0% profit margin vs -24.6%. VTRS appears more attractively valued with a PEG of 0.14. VTRS earns a higher WallStSmart Score of 50/100 (C-).
PCRX
Hold40
out of 100
Grade: D
VTRS
Buy50
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1893.6%
Fair Value
$1.09
Current Price
$23.49
$22.40 premium
Intrinsic value data unavailable for VTRS.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Growing faster than its price suggests
Reasonable price relative to book value
Areas to Watch
Smaller company, higher risk/reward
ROE of 1.0% — below average capital efficiency
1.0% margin — thin
Expensive relative to growth rate
ROE of -21.1% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : PCRX
The strongest argument for PCRX centers on Price/Book.
Bull Case : VTRS
The strongest argument for VTRS centers on PEG Ratio, Price/Book. PEG of 0.14 suggests the stock is reasonably priced for its growth.
Bear Case : PCRX
The primary concerns for PCRX are Market Cap, Return on Equity, Profit Margin. A P/E of 138.2x leaves little room for execution misses. Thin 1.0% margins leave little buffer for downturns.
Bear Case : VTRS
The primary concerns for VTRS are Return on Equity, EPS Growth, Altman Z-Score.
Key Dynamics to Monitor
PCRX profiles as a value stock while VTRS is a turnaround play — different risk/reward profiles.
VTRS carries more volatility with a beta of 0.80 — expect wider price swings.
PCRX is growing revenue faster at 5.1% — sustainability is the question.
VTRS generates stronger free cash flow (551M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (50/100 vs 40/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Pacira BioSciences, Inc.
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare professionals and their patients in the United States. The company is headquartered in Parsippany, New Jersey.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?